Physician profile
Jenay Lisbon
NPI 1265980023
$2,261.05
in general payments reported to CMS, 2019-2025
17 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $197 · 2023: $317 · 2024: $1,188 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $435.15 | 2021-2024 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $381.93 | 2023-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.41 | 2023-2025 | Caplyta |
| Indivior INC. | $209.78 | 2022-2025 | Sublocade |
| Alkermes, INC. | $143.19 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Astrazeneca Pharmaceuticals Lp | $125.00 | 2021 | |
| Viiv Healthcare Company | $120.86 | 2024 | Dovato |
| Braeburn INC. | $85.21 | 2024-2025 | Brixadi |
| Abbvie INC. | $81.68 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $74.61 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $66.96 | 2023-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $59.08 | 2024 | |
| Exact Sciences Corporation | $52.01 | 2023-2024 | Cologuard Collection Kit |
| Orexo US, INC. | $42.28 | 2023-2024 | Zubsolv |
| Lundbeck LLC | $21.70 | 2023 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $15.77 | 2024 | Auvelity |
| Corium, LLC | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenay Lisbon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.